KRAS and lung adenocarcinoma: The predictive value of KRAS and TP53 mutations in lung adenocarcinoma has been investigated in exploratory analyses of data from clinical studies evaluating immunotherapy in NSCLC before, specifically in Checkmate 9LA, Checkmate 227 Part 1, Keynote 042, Keynote 189, and Poseidon [28–32].